Poob 19.7% qhov hnyav hauv 24 lub lis piam! Tsoom Fwv Teb Chaws Pharmaceutical X Novo Nordisk GLP-1 / GIP / GCG triple phiaj agonist poob phaus theem 1 txoj kev kawm tiav
Thaum Lub Ob Hlis 24, 2026, FedEx International Holdings Limited (FedEx) thiab Novo NordiskAS koom ua ke tso tawm cov txiaj ntsig tseem ceeb ntawm Theem 11 kev soj ntsuam ntawm GLP-1 / GIP / GCG triple target receptor agonist JBT251 hauv Suav teb.
Semaglutide hmoov CAS 910463-68-2
1.Peb muab
(1) Tablet
(2) Cov
(3) Capsule
(4) Txau
(5) API (Ntshiab hmoov)
(6) Pill press machine
https://www.achievechem.com/pill-xwm
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
PIB: BM-2-4-008
Semaglutide CAS 910463-68-2
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Kev them nyiaj yug Technology: R&D Dept.-4
Peb muab Semaglutide Powder, thov xa mus rau lub vev xaib hauv qab no kom paub meej cov lus qhia thiab cov khoom lag luam.
Khoom siv:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2.html
UBT251 yog koom ua ke tsim los ntawm Tsoom Fwv Teb Chaws Biotech (Zhuhai Hengqin) Co., Ltd. (Tsoomfwv Biotech), ib tug nkaus -tsoom fwv cov koom haum ntawm Tsoom Fwv Pharmaceuticals, thiab Novo Nordisk raws li daim ntawv tso cai daim ntawv cog lus kos npe rau lub Peb Hlis 2025. Tsoom Fwv Teb Chaws Biotech yog lub luag hauj lwm rau kev loj hlob nyob rau hauv Tuam Tshoj cheeb tsam tshwj xeeb, Hong Kong thiab Mainland. Taiwan, thaum Novo Nordisk yog lub luag haujlwm rau kev txhim kho thoob ntiaj teb ntxiv rau cov lus hais saum toj no.
Qhov kev tshawb fawb soj ntsuam no tau ua los ntawm Tsoom Fwv Teb Chaws Biotech los tshawb xyuas kev nyab xeeb thiab kev ua tau zoo ntawm kev txhaj tshuaj txhua lub lim tiam ntawm 2mg, 4mg, thiab 6mg koob tshuaj UBT251 hauv cov neeg mob rog lossis rog hauv Suav teb piv rau cov tshuaj placebo. Qhov nruab nrab qhov hnyav ntawm tus neeg mob yog 92.2 kg. Tom qab 24 lub lis piam ntawm kev kho mob, pab pawg kho mob UBT251 tau pom qhov poob qis tshaj plaws ntawm 19.7% (-17.5kg), thaum pab pawg placebo tsuas yog txo qis ntawm 2.0% (-1.6kg).
Tsis tas li ntawd, piv nrog cov placebo pab pawg, tag nrho cov koob tshuaj ntawm UBT251 tau pom qhov kev txhim kho tseem ceeb hauv cov ntsiab lus tseem ceeb, suav nrog lub duav ncig, ntshav qabzib, ntshav siab, thiab ntshav lipids.
Hauv qhov kev tshawb fawb no, UBT251 tau pom tias muaj kev nyab xeeb zoo thiab ua haujlwm ntev. Qhov tshwm sim tsis zoo tshaj plaws yog kev mob plab hnyuv, feem ntau ntawm cov mob me me mus rau nruab nrab thiab maj mam txo lub sijhawm, ua raws li kev kho mob raws li enteropancreatin.
2.1 billion US dollars! Novo Nordisk tab tom twv rau tiam tom ntej ntawm cov tshuaj poob qhov ncauj
Thaum Lub Ob Hlis 25, 2026, Novo Nordisk thiab Vivtex tshaj tawm kev tsim kev sib koom tes sib koom ua ke los tsim cov tiam tom ntej ntawm cov tshuaj lom neeg lub qhov ncauj rau kev kho mob rog, ntshav qab zib thiab lwm yam teeb meem. Raws li cov lus pom zoo, Vivex yuav tso cai rau qee qhov kev xa tshuaj hauv qhov ncauj rau Novo Nordisk, thiab tsim nyog tau txais txog li $ 2.1 nphom hauv cov nyiaj them ua ntej, cov nyiaj them tseem ceeb rau kev tshawb fawb nyiaj txiag, thiab cov nqi qis rau kev muag khoom yav tom ntej.
Tshwj xeeb, qhov kev sib koom tes no yog txhawm rau ua tiav kev tswj hwm qhov ncauj ntawm cov tshuaj biopharmaceutical tus neeg sib tw, uas feem ntau tsuas yog siv los ntawm kev txhaj tshuaj vim kev nqus tsis zoo hauv plab hnyuv. Qhov kev sib koom tes no sib koom ua ke Novo Nordisk cov kev txawj ntse hauv peptide thiab cov tshuaj protein nrog Vvtex qhov kev tshuaj ntsuam xyuas plab hnyuv thiab cov txheej txheem tsim los tsim cov tiam tom ntej ntawm cov tshuaj hauv qhov ncauj. Raws li daim ntawv cog lus kev koom tes ntawm ob tog, Novo Nordisk yuav yog lub luag haujlwm rau kev txhim kho thoob ntiaj teb, kev tswj hwm txoj haujlwm, kev tsim khoom, thiab kev lag luam ntawm cov khoom lag luam.
GSK kab mob siab B AS0 Kev Kho Mob Bepirovirsen tau tshaj tawm rau npe hauv Nyij Pooj
Thaum Lub Ob Hlis 26, 2026, GlaxoSmithKline (GSK) tshaj tawm tias Beplovirsen, tshuaj tshiab rau cov kab mob siab B, tau xa daim ntawv thov rau npe hauv Nyij Pooj. GSK ntseeg tias Beplovirsen xav tias yuav dhau los ua thawj cov tshuaj kom ua tiav kev kho mob ntawm tus kab mob siab B.
Bepirovesen yog ib qho tshuaj tua kab mob oligonucleotide (ASO) kev kho mob qhia los ntawm GSK los ntawm Ionis, tsom rau inhibiting replication ntawm tus kab mob siab B tus kab mob DNA, yog li suppressing qib ntawm kab mob siab B nto antigen (HBsAg) hauv cov ntshav thiab txhawb lub cev tiv thaiv kab mob los tsim cov lus teb tsis tu ncua. Cov tshuaj no yog thawj cov tshuaj me me nucleic acid hauv thaj tsam ntawm kab mob siab B mob ntev uas tau ua tiav cov kev tshawb fawb Sichuan theem. Daim ntawv teev npe no yog raws li cov ntaub ntawv zoo los ntawm ob qhov kev tshawb fawb Phase I (B-Wel1 thiab B-Well2).
Txoj kev tshawb no tau soj ntsuam cov kev ua haujlwm kho mob, kev nyab xeeb, tshuaj pharmacokinetics thiab kev ua tau zoo ntawm Bepirovirsen piv nrog cov placebo hauv cov neeg mob kab mob siab B mob ntev uas kho nrog nucleoside analogues thiab nrog cov hauv paus HBSAg Tsawg dua lossis sib npaug rau 3000IU / ml. Thawj qhov kawg yog qhov kev ua haujlwm kho mob ntawm cov neeg mob uas muaj HBsAg Tsawg dua lossis sib npaug ntawm 3000IU / ml, thiab qhov tseem ceeb thib ob qhov kawg yog qhov kev kho mob ntawm cov neeg mob uas muaj HBsAg qis dua lossis sib npaug rau 1000IU / ml.
Eli Lilly Orforglipron swb qhov ncauj semaglutide taub hau rau lub taub hau, ua tiav ob qho txiaj ntsig hauv kev txo cov ntshav qab zib thiab qhov hnyav.
Thaum Lub Ob Hlis 26, 2026, Lilly tau tshaj tawm cov ntsiab lus ntxaws ntawm ACHIEVE-3 txoj kev kawm. ACHIEVE-3 yog thawj lub taub hau rau lub taub hau tswj kev kawm hauv cov kev tshawb fawb no, uas yog lub hom phiaj los ntsuas kev nyab xeeb thiab kev ua tau zoo ntawm orforglipron thiab qhov ncauj smeglutide hauv hom 2 mob ntshav qab zib cov neeg laus uas tsis muaj ntshav qabzib tswj tau kho nrog ob leeg leeg.
Orforglipron yog ib qho me me ntawm qhov ncauj GLP-1 receptor agonist uas tau noj yam tsis muaj kev noj haus lossis dej txwv. Txoj kev tshawb no tau siv sijhawm 52 lub lis piam thiab suav nrog 1698 tus neeg koom, muab faib ua plaub pawg kho mob: orforglipron 12mg thiab 36mg, nrog rau qhov ncauj semaglutide 7mg thiab 14mg. Hauv txoj kev tshawb fawb ACHIEVE-3, orforglipron tau ua tiav qhov ncauj qhov ncauj semaglutide hauv thawj qhov kawg thiab tag nrho cov ntsiab lus tseem ceeb thib ob, ua tiav qhov kev txhim kho tseem ceeb hauv kev txo qis A1C thiab kev txhim kho qhov hnyav.
Txoj kev tshawb fawb ACHIEVE-3 tau qhia tias tag nrho kev nyab xeeb thiab kev zam ntawm orforglipron yog zoo ib yam nrog cov kev tshawb fawb yav dhau los. Feem ntau cov kev phiv tshwm sim ntawm orforglipron thiab qhov ncauj semaglutide yog xeev siab, raws plab, ntuav, plab zom mov, thiab tsis qab los noj mov. Ntawm lawv, qhov kev txiav tawm ntawm 0rforglipron vim yog cov xwm txheej tsis zoo yog 8.7% hauv 12mg pawg thiab 9.7% hauv pawg 36mg, raws li; Qhov kev txiav tawm ntawm qhov ncauj semaglutide yog 4.5% hauv pawg 7mg thiab 4.9% hauv pawg 14mg.
Orforglipron yog ib qho me me molecule (tsis yog peptide) glucagon zoo li peptide-1 receptor agonist (GLP-1 RA) uas tam sim no nyob rau hauv txoj kev loj hlob thiab tswj qhov ncauj ib hnub ib zaug. Cov tshuaj no tuaj yeem noj txhua lub sijhawm ntawm hnub tsis muaj kev txwv rau kev noj zaub mov thiab dej kom tsawg. Cov tshuaj no tau tshawb pom los ntawm ChugaiI Pharmaceutical Co., Ltd thiab tau tso cai tsim los ntawm Eli Lilly hauv 2018. Zhongwai Pharmaceutical thiab Eli Lilly tau koom ua ke luam tawm cov ntaub ntawv tshuaj kho mob preclinical rau cov molecule no.